Aboard Air Force One (AFP) | 15/05/2026 - 13:11:51 | Trump says Xi 'feels strongly' Iran can't have nuclear weapon ...
OXBRYTA's market potential is driven by its novel mechanism targeting HbS polymerization in sickle cell disease, leading to strong hemoglobin improvements. Its convenient oral, once-daily dosing ...
Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –– High CRc rates (90–96%) ...
KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization –– Robust new patient starts and early ...
The Liquid Advantage: The dietary supplement market has seen a shift toward liquid formats. The Glycotide liquid drop ...
Gilead Sciences, Inc. will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona.
KOMZIFTI (ziftomenib) net product revenue in first full quarter of commercialization - - Robust new patient starts and early launch dynamics, including repeat use, switching and combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results